The study demonstrated that prescription rates for both SGLT-2 inhibitors and GLP-1 agonists varied widely, with general cardiologists and heart failure specialists showing higher rates of prescribing these drugs compared to other subspecialties, such as interventional cardiology and electrophysiology. The gene discussed is GLP1R; the disease is heart failure.